Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Simplirix
- Development stage
- Phase 3
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Simplirix (GSK208141) is a protein-based viral subunit vaccine developed for the prevention of genital herpes caused by herpes simplex virus type 2 (HSV-2). The active component is a truncated form of the HSV-2 glycoprotein D (gD), formulated with an adjuvant to enhance immunogenicity. The mechanism of action involves immunostimulation—eliciting an immune response against HSV-2 to prevent infection. Developed by GlaxoSmithKline in collaboration with the National Institute of Allergy and Infectious Diseases and originally originated at Genentech. Despite reaching phase III clinical trials for prevention of genital herpes in seronegative individuals and those at risk for HSV infection in multiple regions including the US and EU, development was discontinued after failing to demonstrate sufficient efficacy[1][4].
- Brand names
- Simplirix
- Other names
- Herpes simplex glycoprotein vaccine - GSKGenital herpes prophylaxis vaccine - GSKHSV vaccine SmithKline BeechamHerpes virus subunit vaccine GlaxoSmithKlineHerpesvirus subunit vaccine SBMPL herpes vaccine GSKGD2 subunit herpes vaccine + MPL SmithKline BeechamGD2 subunit herpes vaccine + SBAS4 GlaxoSmithKline
Beyond the preview
Go deeper on Simplirix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Simplirix.